We are very happy to welcome Dr. Lena Herich and our new trainee Kim Hoang in our team. Lena joined Staburo earlier this year with her work experience and her excellent education background. She supports our clients in the areas of biostatistics & statistical...

Staburo presentation on precision medicine @idalab Dr. Nicole Krämer, project leader precision medicine and biomarkers, was invited to talk about precision medicine at the idalab seminar. In the talk, she discussed how data science may identify biomarkers that help...

Staburo’s Managing Director Roland Stieger will join the BIO-Europe for the fourth time and will enjoy the good organization and networking opportunities of this partnering conference. For the first time, we will have our own booth at the bavarian pavilion. At our...

Pilot study on Effectiveness of Cannabis to Reduce Opioid Addiction We recently performed the analysis for a pilot study, investigating whether cannabis consumption may be beneficial in helping people reduce their addiction to opioids. The results were also presented...

Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study With the help of Staburo, a typeset manuscript has been published in its final form on the Dove Medical Press Ltd website....

Staburo supported Scientific Advice at BfArM Staburo's Managing Director Josef Höfler prepared and took part in a Scientific Advice meeting at the agency BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) in Bonn. At the BfArM, roughly 1,000 employees...

Staburo Wiesn Workshop It is a very nice custom to have our Staburo statistics training session on the first Monday of the two-week Oktoberfest period. This year, the Staburo team had the chance to learn about the "Comparison of adaptive enrichment designs in clinical...

Biomarker analyses published in JAMA Oncology Staburo supported biomarker analyses for a phase III lung-cancer trial. The paper, which was recently published in JAMA Oncology, is a retrospective analysis to assess the association of ErbB mutations with clinical...

Staburo contributed to publication in the Journal of Cardiovascular Pharmacology and Therapeutics Staburo could show, once again, its state-of-the-art biostatistics expertise, by supporting this scientific publication. Here, you find a short summary about the study....